SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 2 — Focused Visit (Follow-up) — Joe Frazier

PatientJoe Frazier
Date of birth1962-01-12
IdentifiersMRN HR-BX004-SYN; SSN (made up) 000-04-5590
Document date2026-03-02
AuthorClarence Whitfield, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Two-week review of home blood pressure readings, with liver elastography, ultrasound and hepatology. [S]

History of Present Illness

Mr. Frazier returns two weeks after intake with a week of home blood pressure readings, twice a day, averaging 146/90. He is taking metformin, lisinopril and the new atorvastatin without trouble. This morning he had liver elastography and a liver ultrasound, and he saw Dr. Deshpande of hepatology. He has had no swelling of the legs or abdomen, no black stools, no confusion and no yellowing. He drinks one or two beers on some weekends and agreed today to stop. He asked what a scarred liver means for his work at the gym. [S]

ElementDetail
Home blood pressureAverage 146/90 over seven days
AtorvastatinTwo weeks; no muscle aches
Liver symptomsNone
AlcoholAgreed to stop

Review of Systems

SystemResultFinding
GastrointestinalNegativeNo abdominal swelling, black stools or vomiting of blood
MusculoskeletalNegativeNo muscle aches on atorvastatin
NeurologicalNegativeNo confusion or day-night reversal

3 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Metformin 1000 mg oral tablet, one tablet twice daily with meals; taken for yearsOne tablet twice daily with mealsOral route2026-02-16activeS
Lisinopril 20 mg oral tablet, one tablet daily; taken for yearsOne tablet dailyOral route2026-02-16activeS
Atorvastatin 40 mg oral tablet, one tablet dailyOne tablet dailyOral route2026-02-16activeS
Amlodipine 5 mg oral tablet, one tablet dailyOne tablet dailyOral route2026-03-02 to 2026-04-13completedS
Semaglutide pen (0.25 mg or 0.5 mg per dose), 0.25 mg under the skin once weekly for four weeks, then 0.5 mg once weekly0.25 mg weekly for four weeks, then 0.5 mg weeklySubcutaneous route2026-03-02 to 2026-05-18completedS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
2026-03-02Body height182cmS
2026-03-02Body weight103.6kgS
2026-03-02Body mass index (BMI) [Ratio]31.3kg/m2S
2026-03-02Systolic blood pressure148mm[Hg]S
2026-03-02Diastolic blood pressure90mm[Hg]S
2026-03-02Heart rate74/minS
2026-03-02Respiratory rate16/minS
2026-03-02Body temperature36.6CelS
2026-03-02Oxygen saturation in Arterial blood by Pulse oximetry97%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
2026-03-02Liver stiffness by US.transient elastography17.6kPaBelow 8 kPa makes advanced fibrosis unlikely; 15 kPa or higher is consistent with compensated advanced chronic liver diseaseHighS
2026-03-02INR in Platelet poor plasma by Coagulation assay1.1{INR}0.8-1.2NormalS
2026-03-02Alpha-1-Fetoprotein [Mass/volume] in Serum or Plasma4.2ng/mL<=8.3 ng/mLNormalS

Physical Exam

Vital signs recorded on 2026-03-02; see the Vital Signs section. [S]

SystemFinding
GeneralWell; blood pressure 148/90, pulse 74; weight 103.6 kg
AbdomenSoft; liver edge firm at the costal margin; spleen tip not felt; no ascites
SkinNo jaundice, spider angiomas or palmar erythema
NeurologicalNo asterixis

Problems

ProblemClinical statusVerificationCodeProvenance
Type 2 diabetes with hyperglycemia, about twelve years' duration, A1c 8.4% on metformin; synthetic modern episode linked to his publicly reported diabetesactiveconfirmed E11.65S — Synthetic modern diagnosis; diabetes was reported publicly during his life, but its duration and treatment here are synthetic.
Hypertension above goal on lisinopril (152/92 mmHg in the clinic); synthetic modern episode linked to his publicly reported high blood pressureactiveconfirmed I10S — Synthetic modern diagnosis; high blood pressure was reported publicly during his life.
Raised AST (48 U/L) with mildly low platelets (138) and a FIB-4 score of 3.43 at the yearly liver check, to be evaluatedresolvedconfirmed R74.01S — Synthetic presenting finding, superseded at the two-week visit by the elastography and ultrasound diagnosis.
Metabolic dysfunction-associated steatotic liver disease (MASLD): steatosis on elastography (controlled attenuation parameter 318 dB/m) and ultrasound, with diabetes, obesity, low HDL and high triglycerides, and little alcoholactiveconfirmed K76.0S — Synthetic modern diagnosis. Not part of the public record of his life; chosen to teach surveillance.
Compensated cirrhosis (compensated advanced chronic liver disease) from MASLD: liver stiffness 17.6 kPa, platelets 138, nodular liver surface and a spleen of 13.4 cm on ultrasound; no ascites, encephalopathy, bleeding or jaundice; Child-Pugh Aactiveconfirmed K74.69S — Synthetic modern diagnosis. Not part of the public record of his life; the liver cancer diagnosed three years later in the true frame does not appear in the modern episode.
Hyperlipidemia: LDL 132 mg/dL, HDL 38 and triglycerides 210, not on a statinactiveconfirmed E78.5S — Synthetic laboratory finding.
Obesity, class 1 (BMI 31.4)activeconfirmed E66.811S — Synthetic finding; described without stigma.
Reduced vision in the left eye since a cataract found at 20 (counting fingers at 1 meter); right eye 20/30activeconfirmed H54.62S — Synthetic modern measurement anchored to the documented cataract in his left eye.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
ExaminationBlood pressure (clinic and home), weight and BMIEvery visitCompleted today148/90 in the clinic; home average 146/90; weight 103.6 kg
LaboratoryHemoglobin A1cEvery 3 months until at goal or after a change in treatment, then every 6 monthsUp to date8.4% two weeks ago; next in three months
Medication safetyLow blood sugar review and medicine tolerabilityEvery visitCompleted todayNo low blood sugar; metformin tolerated
LaboratoryLipid panel4 to 12 weeks after starting a statin, then yearlyUp to dateAtorvastatin started two weeks ago; lipids at eight weeks
LaboratoryPotassium, creatinine and eGFR (CKD-EPI 2021) on lisinoprilEvery 6 months on an ACE inhibitor, and after changesUp to datePotassium 4.6, creatinine 1.08 mg/dL, eGFR 77 two weeks ago
LaboratoryUrine albumin-to-creatinine ratioYearlyUp to date18 mg/g two weeks ago
LaboratoryLiver tests with FIB-4Yearly with diabetes; FIB-4 1.3 or higher leads to elastographyUp to dateFIB-4 3.43 two weeks ago (age 64, AST 48, ALT 42, platelets 138): high risk
ImagingTransient elastographyWhen FIB-4 is 1.3 or higher; repeat in 1 to 2 yearsCompleted todayLiver stiffness 17.6 kPa; controlled attenuation parameter 318 dB/m
ImagingLiver ultrasound with AFP for hepatocellular carcinoma surveillanceEvery 6 months in cirrhosisCompleted todayBaseline ultrasound without a focal lesion; AFP 4.2 ng/mL
LaboratoryLiver function (albumin, bilirubin, INR, platelets; Child-Pugh and MELD)At diagnosis, then every 6 monthsCompleted todayINR 1.1, albumin 4.0, bilirubin 0.9, platelets 138; Child-Pugh A5, MELD 8
ReferralVariceal screeningEndoscopy when portal hypertension cannot be ruled out; repeat in 2 years if no varices and the liver injury continuesOrderedUpper endoscopy booked for next month
Self-managementAlcohol abstinenceEvery visitCompleted todayAgreed to stop the occasional beer
Self-managementNo NSAIDs; acetaminophen no more than 2 g a dayEvery visitCompleted todayExplained; he uses no pain medicine now
Self-managementVaccines for diabetes and chronic liver diseaseAt diagnosis of chronic liver diseaseCompleted todayPCV20 and first doses of hepatitis A and B vaccines today
ReferralHepatology consultationAt diagnosis of advanced fibrosis or cirrhosisCompleted todaySeen by Dr. Deshpande today
Self-managementMedicine cost and coverageWith each new medicineCompleted todaySemaglutide approved after prior authorization; generics for the rest

Goal progress:

Immunizations given today: Pneumococcal conjugate vaccine PCV20; Hepatitis B vaccine (HepB-CpG), dose 1 of 2; Hepatitis A vaccine, adult, dose 1 of 2 [S]

Guideline basis: 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2026 (2026); 4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Care in Diabetes-2026 (2026); 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults (2025); AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease (now metabolic dysfunction-associated steatotic liver disease) (2023); AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma (2023); Baveno VII - Renewing consensus in portal hypertension (2022); Adult Immunization Schedule by Medical Condition and Other Indication (2026); CMID: Clinical Monitoring Intelligence Database, diabetes type 2, hypertension and hyperlipidemia monographs (2026)

Follow-up: Endoscopy next month. Visit in six weeks with lipids, potassium, creatinine and home readings. Diabetes class. Next scheduled visit 2026-04-13: eight-week review: blood pressure, lipids, kidney function, semaglutide, the endoscopy result and vaccines. [S]